Ono Pharmaceutical (4528) · RiskReframed
Litigation risks relating to product liability, antitrust law, environmental matters and other issues
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2023.
3entries
8years
0from disclosures
How it moved
Same theme, other companies
Complex Litigation Risk Relating to Pharmaceuticals, Product Liability, Labor, and Fair TradeA theme 6 companies write about · 6 as a headwind · 0 as a tailwind
Ono Pharmaceutical moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Reframed".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2023ReframedAnnual report
「In connection with the Group’s business activities, it may face lawsuits relating to adverse drug reactions, product liability (PL), labor issues, fair trading issues and environmental issues.」
The existing litigation risks relating to product liability, antitrust law and environmental matters have been organized as litigation risks across the Group’s business activities, including adverse drug reactions, labor issues and fair trading. - FY2018RestatedAnnual report
「The Group may face lawsuits relating to product liability (PL), antitrust law, environmental matters and other issues.」
Litigation risks relating to product liability, antitrust law, environmental matters and other issues have been reiterated. - FY2016First statedAnnual report
「The Group may face lawsuits relating to product liability (PL), antitrust law, environmental matters and other issues.」
The possibility of litigation in multiple legal areas is identified as a risk that could affect operating results and financial position.